II
NBIX icon

IFM Investors’s Neurocrine Biosciences NBIX Stock Holding History

IFM Investors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.99M Buy
23,672
+2,517
+12% +$373K 0.03% 460
2026
Q1 		$2.79M Sell
21,155
-161
-0.8% -$21.4K 0.02% 491
2025
Q4 		$3.02M Buy
21,316
+1,481
+7% +$215K 0.03% 472
2025
Q3 		$2.82M Hold
19,835
– – 0.02% 467
2025
Q2 		$2.49M Buy
19,835
+1,453
+8% +$167K 0.02% 477
2025
Q1 		$2.03M Sell
18,382
-608
-3% -$77K 0.02% 502
2024
Q4 		$2.59M Sell
18,990
-469
-2% -$58K 0.03% 478
2024
Q3 		$2.24M Hold
19,459
– – 0.02% 516
2024
Q2 		$2.68M Buy
19,459
+782
+4% +$107K 0.03% 475
2024
Q1 		$2.58M Buy
18,677
+444
+2% +$60.6K 0.03% 481
2023
Q4 		$2.4M Hold
18,233
– – 0.03% 456
2023
Q3 		$2.05M Buy
18,233
+511
+3% +$53.8K 0.03% 501
2023
Q2 		$1.67M Sell
17,722
-14
-0.1% -$1.37K 0.02% 539
2023
Q1 		$1.8M Buy
17,736
+1,400
+9% +$146K 0.03% 509
2022
Q4 		$1.95M Sell
16,336
-1,246
-7% -$146K 0.03% 467
2022
Q3 		$1.87M Sell
17,582
-239
-1% -$24.3K 0.03% 463
2022
Q2 		$1.74M Sell
17,821
-262
-1% -$24.2K 0.03% 494
2022
Q1 		$1.7M Buy
18,083
+2,466
+16% +$209K 0.03% 510
2021
Q4 		$1.33M Buy
15,617
+903
+6% +$83.1K 0.02% 546
2021
Q3 		$1.41M Buy
14,714
+741
+5% +$70K 0.03% 518
2021
Q2 		$1.36M Buy
13,973
+3,877
+38% +$372K 0.03% 550
2021
Q1 		$982K Buy
10,096
+1,292
+15% +$135K 0.03% 546
2020
Q4 		$844K Buy
8,804
+1,577
+22% +$152K 0.03% 537
2020
Q3 		$695K Buy
7,227
+708
+11% +$81.9K 0.03% 492
2020
Q2 		$795K Sell
6,519
-900
-12% -$99.5K 0.04% 410
2020
Q1 		$680K Sell
7,419
-34
-0.5% -$3.33K 0.03% 474
2019
Q4 		$801K Buy
+7,453
New +$780K 0.03% 527

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

IFM Investors's NBIX Position: Q2 2026 in Review

IFM Investors increased its Neurocrine Biosciences (NBIX) stake by 12% in Q2 2026, buying an estimated $373K and bringing the position to 23,672 shares worth $3.99M. The position accounts for 0.03% of the portfolio, ranked #460.

IFM Investors first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. 163 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • IFM Investors held 23,672 shares of Neurocrine Biosciences worth $3.99M as of Q2 2026.
  • IFM Investors bought 2,517 Neurocrine Biosciences shares in Q2 2026, an estimated $373K.
  • Neurocrine Biosciences made up 0.03% of IFM Investors's portfolio in Q2 2026, its #460 holding.
  • IFM Investors first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 163 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.